Loading
A phase 2 trial of cetuximab, toripalimab and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Sun Yat-sen University, now recruiting.
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study is a phase 2, interventional study registered as NCT06547203 by Sun Yat-sen University, with a registry enrolment figure of 34 participants, started 2024-07-18 and due to reach its primary completion in 2026-07-30. Interventions recorded: Cetuximab; Toripalimab; Irinotecan. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.